
DMAC
DiaMedica Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.6331
Open
4.560
VWAP
4.56
Vol
314.98K
Mkt Cap
197.26M
Low
4.350
Amount
1.44M
EV/EBITDA(TTM)
--
Total Shares
37.96M
EV
142.95M
EV/OCF(TTM)
--
P/S(TTM)
--
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.190
+46.15%
--
--
-0.197
+31.11%
--
--
-0.210
+16.67%
Estimates Revision
The market is revising No Change the revenue expectations for DiaMedica Therapeutics Inc. (DMAC) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 16.16%.
EPS Estimates for FY2025
Revise Upward

+2.24%
In Past 3 Month
Stock Price
Go Up

+16.16%
In Past 3 Month
3 Analyst Rating

128.26% Upside
Wall Street analysts forecast DMAC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DMAC is 10.50 USD with a low forecast of 10.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy

128.26% Upside
Current: 4.600

Low
10.00
Averages
10.50
High
11.00

128.26% Upside
Current: 4.600

Low
10.00
Averages
10.50
High
11.00
H.C. Wainwright
NULL -> Buy
upgrade
$10 -> $12
2025-07-18
New
Reason
H.C. Wainwright
Price Target
$10 -> $12
2025-07-18
New
upgrade
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on DiaMedica Therapeutics to $12 from $10 and keeps a Buy rating on the shares. The firm says that with the positive interim results from Part 1a of the Phase 2 study, there is "tangible evidence" for the therapeutic potential of DM199 across achieved pre-specified efficacy and safety endpoints from the dose escalation.
Lake Street
Buy
maintain
$11 -> $14
2025-07-18
New
Reason
Lake Street
Price Target
$11 -> $14
2025-07-18
New
maintain
Buy
Reason
Lake Street raised the firm's price target on DiaMedica Therapeutics to $14 from $11 and keeps a Buy rating on the shares after the company announced interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia that the firm sees "materially" improving the prospects for DM199 in this indication.
Craig-Hallum
Chase Knickerbocker
Buy
maintain
$8 -> $11
2025-07-18
New
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$8 -> $11
2025-07-18
New
maintain
Buy
Reason
Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on DiaMedica Therapeutics to $11 from $8 and keeps a Buy rating on the shares following interim results from Part 1a of its Phase 2 trial evaluating DM199 for preeclampsia. The data showed clinically meaningful reductions in both systolic and diastolic blood pressure, with the highest dose group experiencing acute drops of 35 mmHg and 15 mmHg respectively at 5 minutes. While the sample size remains small, the 24-hour average reductions of 20 mmHg systolic and 10 mmHg diastolic are encouraging and the firm says potentially clinically meaningful. These results support continued development into Part 1b and beyond, Craig-Hallum adds. Importantly, evidence suggests DM199 did not cross the placental barrier.
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Maintains
$7 → $10
2025-03-19
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$7 → $10
2025-03-19
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$7
2024-11-15
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$7
2024-11-15
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$7
2024-10-10
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$7
2024-10-10
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for DiaMedica Therapeutics Inc (DMAC.O) is -5.77, compared to its 5-year average forward P/E of -5.00. For a more detailed relative valuation and DCF analysis to assess DiaMedica Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-5.00
Current PE
-5.77
Overvalued PE
-2.48
Undervalued PE
-7.53
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-2.83
Current EV/EBITDA
-3.41
Overvalued EV/EBITDA
-0.27
Undervalued EV/EBITDA
-5.38
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+41.86%
-8.14M
Operating Profit
FY2025Q1
YoY :
+49.62%
-7.71M
Net Income after Tax
FY2025Q1
YoY :
+28.57%
-0.18
EPS - Diluted
FY2025Q1
YoY :
+7.49%
-7.16M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
113.3K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DMAC News & Events
Events Timeline
2025-07-21 (ET)
2025-07-21
09:19:59
DiaMedica Therapeutics to sell 8.606M shares at $3.50 in private placement

2025-07-17 (ET)
2025-07-17
08:09:07
DiaMedica Therapeutics reports interim results from DM199 study

2025-06-24 (ET)
2025-06-24
09:08:40
DiaMedica Therapeutics to be included in Russell 2000, 3000 Indexes

Sign Up For More Events
Sign Up For More Events
News
4.0
07-18BenzingaCraig-Hallum Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $11
4.0
07-18BenzingaLake Street Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $14
9.0
07-17NewsfilterDiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer
Sign Up For More News
People Also Watch

AVNW
Aviat Networks Inc
23.850
USD
+0.93%

CPSS
Consumer Portfolio Services Inc
8.680
USD
-1.92%

ELDN
Eledon Pharmaceuticals Inc
3.710
USD
+0.54%

GENC
Gencor Industries Inc
13.910
USD
-0.29%

ALTG
Alta Equipment Group Inc
7.630
USD
+3.25%

NAUT
Nautilus Biotechnology Inc
0.735
USD
+1.10%

SBT
Sterling Bancorp Inc
4.870
USD
-0.83%

EVI
EVI Industries Inc
23.280
USD
+0.22%

LFCR
Lifecore Biomedical Inc
7.440
USD
-0.27%

PINE
Alpine Income Property Trust Inc
14.560
USD
+0.83%
FAQ

What is DiaMedica Therapeutics Inc (DMAC) stock price today?
The current price of DMAC is 4.6 USD — it has increased 1.32 % in the last trading day.

What is DiaMedica Therapeutics Inc (DMAC)'s business?

What is the price predicton of DMAC Stock?

What is DiaMedica Therapeutics Inc (DMAC)'s revenue for the last quarter?

What is DiaMedica Therapeutics Inc (DMAC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for DiaMedica Therapeutics Inc (DMAC)'s fundamentals?

How many employees does DiaMedica Therapeutics Inc (DMAC). have?
